To the best of our knowledge, this is the first study on the impact of ABCB1, ABCG2, PXR, and CAR gene polymorphisms on the outcomes of dasatinib treatment in CML. The gene discussed is ABCG2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.